Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
Phase 2
Completed
- Conditions
- Malignant Solid Tumour
- Registration Number
- NCT02853903
- Lead Sponsor
- Fuda Cancer Hospital, Guangzhou
- Brief Summary
The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.
- Detailed Description
By enrolling patients with multiple kinds of solid tumor adapted to enrolled criteria, this study will document for the first time the short/long term efficacy of auto/allogenic NK cells.The outcome will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length < 5 cm
- KPS ≥ 70, lifespan > 6 months
- Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion Criteria
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Relief degree of tumors 3 months It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
- Secondary Outcome Measures
Name Time Method Progress free survival（PFS） 1 year Overall survival（OS） 3 years
Trial Locations
- Locations (1)
Fuda cancer institute of Fuda cancer hospital
🇨🇳Guangzhou, Guangdong, China
Fuda cancer institute of Fuda cancer hospital🇨🇳Guangzhou, Guangdong, China